Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 265 results for "mirati"

Mirati Therapeutics misses by $0.13

To screen ETFs by asset class, performance, yield and more, check out the ETF Hub. Seeking Alpha, 2 weeks ago

1 images for "mirati"

Ticker Report, 2 weeks ago

Mirati reports 1Q loss

On a per-share basis, the San Diego-based company said it had a loss of 77 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks
 Yahoo! UK and Ireland2 weeks ago
[x]  

DEF 14A - Mirati Therapeutics, Inc. (0001576263) (Filer)

Document Format Files Seq Description Document Type Size 1 DEF 14A mirati2015proxy.htm DEF 14A 782941 2 g196472.jpg GRAPHIC 6478 3 g368600.jpg GRAPHIC 3453 4 g641197.jpg GRAPHIC 8973 5 g775045.jpg GRAPHIC 11606 6 g775045a02.jpg GRAPHIC 11606 7 ...
 SEC1 month ago

Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting

SAN DIEGO "We are pleased to participate in the 2015 ASCO Annual Meeting and present the progress we have made with each of Mirati's targeted oncology candidates," said Charles M. Baum Mirati Abstracts Being Presented at ASCO About MGCD265 ...
 ADVFN UK1 week ago Mirati Therapeutics To Provide Updates On Pipeline Programs At 2015 ASCO Annual Meeting  BioSpace1 week ago Mirati Therapeutics : to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting  4 Traders1 week ago Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update  Securities Technology Monitor2 weeks ago
[x]  

Can The Uptrend Continue for Mirati Therapeutics (MRTX)?

These 7 were hand-picked from the list of 220 Zacks Rank #1 Strong Buys with earnings estimate revisions that are sweeping upward. Their stock prices are expected to rise sooner than the others. Today, this Special Report will be available to ...
 Zacks.com1 week ago

Mirati Therapeutics (MRTX) Jumps: Stock Moves Up 6.8%

Today, you are invited to download a free Special Report from Zacks Investment Research. It reveals five moves that could gain +100% and more in the next 12 months: One white-hot electronics company is launching a wave of 9 new products.
 Zacks.com2 months ago

Mirati Therapeutics Inc (MRTX) is Trading Lower on Unusual Volume for May 18

Mirati Therapeutics Inc ( MRTX ) experienced unusually high volume on May. 18, as the stock lost 0.07% to a closing price of $28.30. The stock saw 186,579 shares trade hands over the course of the day on 1,565 trades. Given that the stock's ...
 Equities.com5 days ago Mirati Therapeutics Inc (MRTX) Drops 5.28% on May 21  Equities.com2 days ago Mirati Therapeutics Inc (MRTX) Jumps 5.28% on May 07  Equities.com2 weeks ago Mirati Therapeutics Inc (MRTX) Hits New 52-week High During March 19 Session  Equities.com2 months ago

Commit To Purchase Mirati Therapeutics At $25, Earn 22.6% Annualized Using Options

Investors considering a purchase of Mirati Therapeutics Inc (MRTX) stock, but cautious about paying the going market price of $27.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One ...
 Vision Monday5 days ago
[x]  

Zacks Downgrades Mirati Therapeutics to Hold (MRTX)

Filed Under: Analysts Downgrades • Market News Mirati Therapeutics (NASDAQ:MRTX) was downgraded by Zacks from a buy rating to a hold rating in a report issued on Tuesday. Zacks analyst wrote, Mirati Therapeutics, Inc. is a biopharmaceutical ...
 American Banking News - Forex1 week ago Mirati Therapeutics Cut to Hold at Zacks (MRTX)  Mideast Time1 week ago Mirati Therapeutics Lowered to Hold at Zacks (MRTX)  Ticker Report1 week ago Equities Research Analysts Downgrades for May, 12th (ENTL, ERF, FATE, FLTX, FMCC, FSC, FVE, GCA, GFI, GFSZY)  American Banking News1 week ago

Brean Capital Increases Mirati Therapeutics Price Target to $34.00 (MRTX)

Investment analysts at Brean Capital lifted their price target on shares of Mirati Therapeutics (NASDAQ:MRTX) from $27.00 to $34.00 in a note issued to investors on Friday. The firm currently has a buy rating on the stock. Brean Capital's price ...
 Ticker Report2 weeks ago Brean Capital Boosts Mirati Therapeutics Price Target to $34.00 (MRTX)  Mideast Time1 week ago Mirati Therapeutics Price Target Raised to $35.00 at Leerink Swann (MRTX)  SleekMoney2 weeks ago Leerink Swann Boosts Mirati Therapeutics Price Target to $35.00 (MRTX)  Ticker Report2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less